Ewing Sarcoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	IE Sensitive: A2 - Guideline IE Sensitive : A2	IE Sensitive: A2 - Guideline IE Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	VC Sensitive: A2 - Guideline VC Sensitive : A2	VC Sensitive: A2 - Guideline VC Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	GT Sensitive: A2 - Guideline GT Sensitive : A2	GT Sensitive: A2 - Guideline GT Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	melphalan + busulfan Sensitive: A2 - Guideline melphalan + busulfan Sensitive : A2	melphalan + busulfan Sensitive: A2 - Guideline melphalan + busulfan Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	ifosfamide + cyclophosphamide + etoposide IV + topotecan Sensitive: A2 - Guideline ifosfamide + cyclophosphamide + etoposide IV + topotecan Sensitive : A2	ifosfamide + cyclophosphamide + etoposide IV + topotecan Sensitive: A2 - Guideline ifosfamide + cyclophosphamide + etoposide IV + topotecan Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	temozolomide + irinotecan Sensitive: A2 - Guideline temozolomide + irinotecan Sensitive : A2	temozolomide + irinotecan Sensitive: A2 - Guideline temozolomide + irinotecan Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline temozolomide + irinotecan + vincristine Sensitive : A2	temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline temozolomide + irinotecan + vincristine Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	cyclophosphamide + topotecan Sensitive: A2 - Guideline cyclophosphamide + topotecan Sensitive : A2	cyclophosphamide + topotecan Sensitive: A2 - Guideline cyclophosphamide + topotecan Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline carboplatin + ifosfamide + etoposide IV Sensitive : A2	carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline carboplatin + ifosfamide + etoposide IV Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	gemcitabine + docetaxel Sensitive: A2 - Guideline gemcitabine + docetaxel Sensitive : A2	gemcitabine + docetaxel Sensitive: A2 - Guideline gemcitabine + docetaxel Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
TMB-H	Ewing Sarcoma	TMB-H	Ewing Sarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : C1	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : C1
MSI-H/dMMR	Ewing Sarcoma	MSI-H/dMMR	Ewing Sarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	VIDE Sensitive: A2 - Guideline VIDE Sensitive : A2	VIDE Sensitive: A2 - Guideline VIDE Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	VAIA Sensitive: A2 - Guideline VAIA Sensitive : A2	VAIA Sensitive: A2 - Guideline VAIA Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	VDC Sensitive: A2 - Guideline VDC Sensitive : A2	VDC Sensitive: A2 - Guideline VDC Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	lurbinectedin Sensitive: A2 - Guideline lurbinectedin Sensitive : A2	lurbinectedin Sensitive: A2 - Guideline lurbinectedin Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	SP2577 Sensitive: B - Late Trials SP2577 Sensitive : B	SP2577 Sensitive: B - Late Trials SP2577 Sensitive : B
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	ONCT-216 Sensitive: B - Late Trials ONCT-216 Sensitive : B	ONCT-216 Sensitive: B - Late Trials ONCT-216 Sensitive : B
MGMT promoter methylation	Ewing Sarcoma	MGMT promoter methylation	Ewing Sarcoma	temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria temozolomide + irinotecan Sensitive : C2	temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria temozolomide + irinotecan Sensitive : C2
IGF1R underexpression	Ewing Sarcoma	IGF1R underexpression	Ewing Sarcoma	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3
IGF1 elevation	Ewing Sarcoma	IGF1 elevation	Ewing Sarcoma	CP-751,871 Sensitive: C3 – Early Trials CP-751,871 Sensitive : C3	CP-751,871 Sensitive: C3 – Early Trials CP-751,871 Sensitive : C3
PTPRD R995C	Ewing Sarcoma	PTPRD R995C	Ewing Sarcoma	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3
PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3
PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	IGF-1R inhibitor Sensitive: C3 – Early Trials IGF-1R inhibitor Sensitive : C3	IGF-1R inhibitor Sensitive: C3 – Early Trials IGF-1R inhibitor Sensitive : C3
SPARC overexpression	Ewing Sarcoma	SPARC overexpression	Ewing Sarcoma	albumin-bound paclitaxel Sensitive: C3 – Early Trials albumin-bound paclitaxel Sensitive : C3	albumin-bound paclitaxel Sensitive: C3 – Early Trials albumin-bound paclitaxel Sensitive : C3
B4GALNT1 expression	Ewing Sarcoma	B4GALNT1 expression	Ewing Sarcoma	dinutuximab beta Sensitive: C3 – Early Trials dinutuximab beta Sensitive : C3	dinutuximab beta Sensitive: C3 – Early Trials dinutuximab beta Sensitive : C3
EWSR1-FLI1 fusion	Ewing Sarcoma	EWSR1-FLI1 fusion	Ewing Sarcoma	VDC Sensitive: C4 – Case Studies VDC Sensitive : C4	VDC Sensitive: C4 – Case Studies VDC Sensitive : C4
FGFR3 amplification + FGFR4 amplification + FLT4 amplification	Ewing Sarcoma	FGFR3 amplification + FGFR4 amplification + FLT4 amplification	Ewing Sarcoma	trametinib + pazopanib Resistant: C4 – Case Studies trametinib + pazopanib Resistant : C4	trametinib + pazopanib Resistant: C4 – Case Studies trametinib + pazopanib Resistant : C4
CD99 positive + VIM positive	Ewing Sarcoma	CD99 positive + VIM positive	Ewing Sarcoma	OPEC Sensitive: C4 – Case Studies OPEC Sensitive : C4	OPEC Sensitive: C4 – Case Studies OPEC Sensitive : C4
IGF1R expression	Ewing Sarcoma	IGF1R expression	Ewing Sarcoma	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D

Ewing Sarcoma

Associations(42)

Associations
(42)